A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502380-37-00

Acronym

1698-301-007

Enrollment

167

Registered

2023-09-04

Start date

2019-08-02

Completion date

2025-07-11

Last updated

2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-Angle Glaucoma, Ocular Hypertension

Brief summary

Duration of effect of Bimatoprost SR

Detailed description

Adverse events; visual fields; visual acuity; macroscopic bulbar conjunctival hyperemia; slit-lamp biomicroscopic assessments; dilated ophthalmoscopic assessments (including optic disc assessment); contact ultrasound pachymetry; gonioscopy; specular microscopy

Interventions

DRUGBimatoprost SR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Duration of effect of Bimatoprost SR	—

Secondary

Measure	Time frame
Adverse events; visual fields; visual acuity; macroscopic bulbar conjunctival hyperemia; slit-lamp biomicroscopic assessments; dilated ophthalmoscopic assessments (including optic disc assessment); contact ultrasound pachymetry; gonioscopy; specular microscopy	—

Countries

Bulgaria, Czechia, Denmark, Germany, Ireland, Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026